Last week marked a very exciting moment for anyone with any involvement in breast cancer patient care, including, and especially, for breast cancer patients. On February 22 2013, the FDA approved Kadcyla, a new treatment for HER-2 positive metastatic breast cancer. Kadcyla was formerly known to many in the cancer world as T-DM1 and has … Continue reading New hope in HER-2 Positive Metastatic Breast Cancer
2013 needs to be a year of major, actionable change in pharma.
I am also writing about creativity squashers in Big Pharma in my mini-series “Are you there, Pharma? It’s me, Liz.”
- Are you there, Pharma? It’s me, Liz. Part One: Listening and Acting (pugtato.com)
- Are you there Pharma? It’s me, Liz. Part two: What’s Killing Creativity in Big Pharma Sales Forces? (pugtato.com)
- 13 digital pharma predictions for 2013 (pharmastrategic.com)
- BulletinHealthcare a TOP 10 “Most Innovative Company” of 2012 According to Pharma Marketing Publication PM360 (prweb.com)
- ‘Bad Pharma’ says we’re all victims of drug industry (engineeringevil.com)
- Pharma Marketing to Physicians for 2012 [INFOGRAPHIC] (medmeme.com)
The familiar rituals of festive celebration can be a comfort to many, and prudent hosts remember that such occasions are not a time for innovation. Family, friends and guests are more likely to enjoy the shared pleasures of participating in a ritual’s traditions than they are to be craving diversion from its norms.
However, beyond a certain point the appeal of the familiar can quickly wane. Not only can we have a surfeit of convention; we can also become thoroughly nauseated by it.
Reviewing some of the customary ‘New Year’s predictions for pharma’ posts on returning to my desk this week, I felt more than a little queasy (this post by Digitally Sick colleague Alex Butler being a notable exception).
Unlike the celebrations that precede it, the New Year is a time to take a fresh look at the problems that confront us, not merely to resume…
View original post 399 more words
Welcome back to the second post in my series, "Are you there Pharma? It's me, Liz." This series identifies creative thinking squashers in Pharma and suggests strategic changes that will help Big Pharma to improve its business model, in hopes of radically changing the way Pharma goes about its business. The first post discussed … Continue reading Are you there Pharma? It’s me, Liz. Part two: What’s Killing Creativity in Big Pharma Sales Forces?
As an ex-pharma veteran, I have experienced first hand, the challenges that Big Pharma faces as it struggles to figure out how to compete in a radically changing healthcare system. This mini series focuses on some changes that I would love to see in the industry, and quite frankly, changes that are necessary if Pharma … Continue reading Are you there, Pharma? It’s me, Liz. Part One: Listening and Acting